PTNR 5.77 Partner Communications Company Ltd $PTNR Hit a 52

New Post Public Reply Private Reply Replies (0) Message Board
Emylers
PTNR 5.77 Partner Communications Company Ltd $PTNR Hit a 52 week low of 5.77 Closing the day 10:43 at 5.77 -0.11 -1.87% With a day low of 5.77 and a total volume of 14,223.

PTNR Recent Posts: http://investorshangout.com/Partner-Communica...TNR-55201/

PTNR Partner Communications Company Ltd Recent Headline News

Partner Communications' (PTNR) CEO Haim Romano on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 11:43AM CST

PTNR: 5.77 (-0.11)

Partner Communications Company (PTNR) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 12, 8:55AM CST

PTNR: 5.77 (-0.11)

Partner Communication EPS of NIS0.26
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 5:49AM CST

PTNR: 5.77 (-0.11)

CORRECTING and REPLACING, Partner Communications Reports Third Quarter 2014 Results(1)
Business Wire - Wed Nov 12, 4:49AM CST
--NET DEBT TOTALED NIS 2.6 BILLION, A DECREASE OF NIS 571 MILLION SINCE SEPTEMBER 2013
PTNR: 5.77 (-0.11)

Partner Communications Reports Third Quarter 2014 Results(1)
Business Wire - Wed Nov 12, 2:36AM CST
--NET DEBT TOTALED NIS 2.6 BILLION, A DECREASE OF NIS 571 MILLION SINCE SEPTEMBER 2013
PTNR: 5.77 (-0.11)

Partner Communications Has Returned 25.7% Since SmarTrend Recommendation (PTNR)
Comtex SmarTrend(R) - Tue Nov 11, 5:07PM CST
SmarTrend identified a Downtrend for Partner Communications (NASDAQ TNR) on May 22nd, 2014 at $8.35. In approximately 6 months, Partner Communications has returned 25.70% as of today's recent price of $6.20.
PTNR: 5.77 (-0.11)

17.0% Return Seen to Date on SmarTrend Partner Communications Call (PTNR)
Comtex SmarTrend(R) - Tue Oct 28, 9:56AM CDT
SmarTrend identified a Downtrend for Partner Communications (NASDAQ TNR) on May 22nd, 2014 at $8.35. In approximately 5 months, Partner Communications has returned 16.96% as of today's recent price of $6.93.
PTNR: 5.77 (-0.11)

Partner Communications Reports the Postponement of the 4G Tender Submission Date by the Tender Committee
Business Wire - Wed Oct 22, 10:51AM CDT
Partner Communications Company Ltd. ("Partner" or the "Company" (NASDAQ TNR) (TASE TNR), a leading Israeli mobile communications operator, reports that on October 21, 2014, the tender committee appointed in connection with the 4G frequencies tender (the "Tender" , postponed to November 13, 2014, the date for submitting basic proposals to participate in the Tender. Partner believes that the tender committee's decision was motivated in part by regulatory issues that may be raised regarding cross-ownership within the Israeli telecommunications industry, including among Partner's "Israeli Entities". As defined in Partner's general license for the provision of mobile radio telephone services using the cellular method (MRT) (the "License" , the term "Israeli Entities" means the Israeli founding shareholders or their approved substitutes.
PTNR: 5.77 (-0.11)

Partner Communications Announces the Results of the Annual General Meeting of Shareholders
Business Wire - Wed Oct 22, 2:24AM CDT
Partner Communications Company Ltd. ("Partner" or the "Company" (NASDAQ TNR) (TASE TNR), a leading Israeli communications operator, announces the results of the Annual General Meeting of Shareholders (the "AGM" , that was held on October 21, 2014, at Partner's offices in Rosh Ha'ayin, Israel.
PTNR: 5.77 (-0.11)

Partner Communications Down 16.4% Since SmarTrend Downtrend Call (PTNR)
Comtex SmarTrend(R) - Tue Oct 21, 9:36AM CDT
SmarTrend identified a Downtrend for Partner Communications (NASDAQ TNR) on May 22nd, 2014 at $8.35. In approximately 5 months, Partner Communications has returned 16.36% as of today's recent price of $6.98.
PTNR: 5.77 (-0.11)

Partner Communications to Release Third Quarter 2014 Results on November 12, 2014
Business Wire - Tue Oct 21, 4:01AM CDT
Partner Communications Company Ltd. ("Partner" or "the Company" (NASDAQ TNR) (TASE TNR), a leading Israeli communications operator, announced today that the Company's reviewed financial results for the quarter ended September 30, 2014 will be released on Wednesday, November 12, 2014.
PTNR: 5.77 (-0.11)

Partner Communications Shares Down 14.9% Since SmarTrend's Sell Call (PTNR)
Comtex SmarTrend(R) - Mon Oct 13, 5:13PM CDT
SmarTrend identified a Downtrend for Partner Communications (NASDAQ TNR) on May 22nd, 2014 at $8.34. In approximately 5 months, Partner Communications has returned 14.92% as of today's recent price of $7.10.
PTNR: 5.77 (-0.11)

PGJ, ENY, APH, MNTA, PTNR, IM Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Oct 09, 7:22AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of PowerShares Golden Dragon Halter USX China Portfolio (NYSE GJ), GUGGENHEIM CANADIAN ENERGY I (NYSE:ENY), AMPHENOL CORPORATION (NYSE:APH), Momenta Pharmaceuticals Inc (NASDAQ:MNTA), Partner Communications Company Ltd (NASDAQ TNR), Ingram Micro Inc (NYSE:IM) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
APH: 50.85 (-0.01), IM: 26.99 (+0.05), ENY: 13.39 (-0.07), PTNR: 5.77 (-0.11), PGJ: 31.15 (-0.51), MNTA: 10.70 (+0.07)

Partner Communications Announces the Removal of an Item from the AGM Agenda
Business Wire - Tue Oct 07, 8:43AM CDT
Partner Communications Company Ltd. ("Partner" or "the Company" (NASDAQ TNR) (TASE TNR), a leading Israeli mobile communications operator, announces the removal of item 8 from the agenda of the Annual General Meeting of shareholders scheduled for October 21, 2014, in order to re-examine the issue, insofar as this will be necessary. No change is made to any other item on the AGM agenda.
PTNR: 5.77 (-0.11)

Partner Communications provides interest rate for Series D notes offering
M2 - Mon Oct 06, 6:46AM CDT
Partner Communications Company Ltd (Nasdaq TNR) (TASE TNR.TA), an Israeli communications operator, reported on Monday that the company's Series D notes will bear interest at a rate of 0.355% for the period commencing on 1 October 2014 and ending on 30 December 2014.
PTNR: 5.77 (-0.11)

Partner Communications Reports the Interest Rate for the Series D Notes for the Period Commencing on October 1, 2014 and Ending on December 30, 2014
Business Wire - Mon Oct 06, 1:54AM CDT
Partner Communications Company Ltd. ("Partner" or the "Company" (NASDAQ TNR) (TASE TNR), a leading Israeli communications operator, reports, pursuant to the Company's Shelf Prospectus dated September 3, 2009, as amended to date, and the Supplemental Shelf Offering Report dated April 15, 2010, as amended to date (the "Offering Report" , that the Company's Series D Notes will bear interest at a rate of 0.355% for the period commencing on October 1, 2014 and ending on December 30, 2014.
PTNR: 5.77 (-0.11)

Partner Communications names Issac Benbenisti as Deputy CEO
M2 - Thu Oct 02, 3:50AM CDT
Partner Communications Company Ltd (Nasdaq TNR)(TASE TNR.TA), an Israeli mobile communications operator, announced on Wednesday that it has appointed Issac Benbenisti as its deputy CEO, effective 2 November 2014.
PTNR: 5.77 (-0.11)

Partner Communications Announces the Appointment of Mr. Issac Benbenisti as the Company's Deputy CEO
Business Wire - Wed Oct 01, 3:09AM CDT
Partner Communications Company Ltd. ("Partner" or "the Company" (NASDAQ TNR) (TASE TNR), a leading Israeli mobile communications operator, announces today that the appointment of Mr. Issac Benbenisti as the Company's deputy CEO. Mr. Benbenisti will commence his office on November 2, 2014.
PTNR: 5.77 (-0.11)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 0

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 2

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 0

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 4

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading

Top 5 Most Recently Viewed Articles

Conformal Coatings Market Set for Significant Growth by 2032

Updated Category News Views 233

The conformal coatings market surged ahead with projections showing it could reach USD 1.7 billion by 2032. This translates into a compound annual growth rate (CAGR) of 5.7% from 2024 to 2032, driven primarily by advancements in electronic protection technologies. Traders had better keep their eyes peeled—this ain't just a bump; it's a substantial shift. What’s...

Continue Reading
Japanese Mobile Battery Industry Forecasts Significant Growth

Updated Category News Views 122

Japan Mobile Battery Market Overview The mobile battery market in Japan is witnessing significant growth, with a valuation of JPY 207.96 billion in 2024 and projected to escalate to JPY 358.97 billion by 2033, marking a compound annual growth rate (CAGR) of 6.48% from 2025 to 2033. This growth trajectory highlights not only increasing consumer demands but also rapidly...

Continue Reading
Givastomig: A Promising Player in Gastric Cancer Therapy

Updated Category News Views 74

Givastomig's Advances in Gastric Cancer Research I-Mab (NASDAQ: IMAB), a biotech firm focused on developing cancer immunotherapies, recently presented exciting results from its Phase 1 clinical trial involving givastomig. This innovative bispecific antibody immunostimulant was unveiled at a prominent medical conference, demonstrating its effectiveness in treating advanced...

Continue Reading
Rani Therapeutics Partners with Chugai for Drug Delivery Breakthrough

Updated Category News Views 245

Rani Therapeutics Engages with Chugai Pharmaceutical Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) recently announced a significant collaborative effort with Chugai Pharmaceutical Co., Ltd., resulting in an enthusiastic response from investors. This collaboration aims to utilize Rani's innovative RaniPill oral drug delivery system alongside Chugai's experimental...

Continue Reading
Revizto's Brand Revamp: A Bold Step Towards Future Growth

Updated Category News Views 142

Revizto Introduces a Fresh Brand Identity As project complexities continue to rise in the construction industry, Revizto is making important modifications to its public image. The renowned collaboration platform, specifically designed for the Architecture, Engineering, Construction, and Operations (AECO) sectors, recently unveiled its refreshed brand identity,...

Continue Reading